There is new hope for children with atopic dermatitis (one of the most common forms of eczema.) The FDA has approved DupixentⓇ (dupilumab) injectable for children as young as ago 6. It was previously approved only for ages 12 and older. Up to this point, only topical remedies (such as corticosteroids) or phototherapy could be prescribed for children ages 6-11.
Atopic dermatitis affects approximately 13 percent of all children under the age of 18 in the United States and is considered a chronic, inflammatory condition that is a result of an overactive immune system response to triggers inside and outside the body.
DupixentⓇ, when used with, or even in place of, topical remedies, has been shown to help manage the inflammation deep beneath the surface that contributes to eczema flare-ups. In the pediatric (6-18 years of age) population, a DupixentⓇ injection is given either every two or four weeks, based on weight, following an initial loading dose. DupixentⓇ is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home by self-administration after training by a healthcare professional. Schedule a consultation with the team at Windsor Dermatology to determine if DupixentⓇ is the right choice for your child. Call us today!
